Historique
Bulletin de Périodique
Journal of Psychoactive Drugs , Vol.54, n°4 - September-October 2022
Paru le :
01/10/2022
Année
2022
Page(s) :
295-391
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- Self-reported changes in cannabis use due to the COVID-19 pandemic among US adults. Nguyen N., Keyhani S., Ling P.M., Hoggatt K.J., Hasin D., Cohen B.E., p. 295-299.
- Opioid use disorder and COVID-19: Treatment and recovery factors among vulnerable populations at the intersection of two U.S. epidemics. Banks D.E., Paschke M.E., Li X., Fentem A., Rich A., Szlyk H.S., et al., p. 300-308.
- Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Davis A.K., Agin-Liebes G., Espana M., Pilecki B., Luoma J., p. 309-318.
- A psychonaut's experience of intoxication with multiple classes of drugs including novel psychoactive substance 2-fluorodeschloroketamine: Case report and urinary analysis. Domanski K., Fleming S.W., Maag H., Bouso Raley E., DeBord J., Wright B., et al., p. 319-323.
- Comment and response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. Fitzpatrick C.M., Anderson B.T., Agin-Liebes G., Guydish J., p. 324-327.
- Folktales of recovery - From addiction to becoming a helper: Deep structures of life stories applying Propp's theory: A narrative analysis. Kiss D., Horvath Z., Kassai S., Gyarmathy A.V., Racz J., p. 328-339.
- The role of acceptance and change in recovery from substance use disorders. Chen G., p. 340-347.
- Polydrug use and co-occurring substance use disorders in a respondent driven sampling of cocaine base paste users in Santiago, Chile. Olivari C.F., Gaete J., Rodriguez N., Pizarro E., Del Villar P., Calvo E., et al., p. 348-357.
- Predictors of relapse to alcohol and substance use: Are there any differences between 3 and 12 months after inpatient treatment? Guliyev C., Ince-Guliyev E., Ögel K., p. 358-367.
- Sexual orientation and synthetic cannabinoid use: Examining the role of bullying victimization. Stogner J., Sarvey L., Lowe C.C., Hupli A., Miller B.L., p. 368-377.
- Anxiety-related symptoms following the sporadic use of ecstasy - A case study. Majic T., Brandt L., Montag C., p. 378-385.
- Management of pregabalin use disorder: A case series. Langlumé L., Eiden C., Roy S., Taruffi F., Gambier J., Donnadieu-Rigole H., et al., p. 386-391.
- Self-reported changes in cannabis use due to the COVID-19 pandemic among US adults. Nguyen N., Keyhani S., Ling P.M., Hoggatt K.J., Hasin D., Cohen B.E., p. 295-299.
- Opioid use disorder and COVID-19: Treatment and recovery factors among vulnerable populations at the intersection of two U.S. epidemics. Banks D.E., Paschke M.E., Li X., Fentem A., Rich A., Szlyk H.S., et al., p. 300-308.
- Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Davis A.K., Agin-Liebes G., Espana M., Pilecki B., Luoma J., p. 309-318.
- A psychonaut's experience of intoxication with multiple classes of drugs including novel psychoactive substance 2-fluorodeschloroketamine: Case report and urinary analysis. Domanski K., Fleming S.W., Maag H., Bouso Raley E., DeBord J., Wright B., et al., p. 319-323.
- Comment and response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. Fitzpatrick C.M., Anderson B.T., Agin-Liebes G., Guydish J., p. 324-327.
- Folktales of recovery - From addiction to becoming a helper: Deep structures of life stories applying Propp's theory: A narrative analysis. Kiss D., Horvath Z., Kassai S., Gyarmathy A.V., Racz J., p. 328-339.
- The role of acceptance and change in recovery from substance use disorders. Chen G., p. 340-347.
- Polydrug use and co-occurring substance use disorders in a respondent driven sampling of cocaine base paste users in Santiago, Chile. Olivari C.F., Gaete J., Rodriguez N., Pizarro E., Del Villar P., Calvo E., et al., p. 348-357.
- Predictors of relapse to alcohol and substance use: Are there any differences between 3 and 12 months after inpatient treatment? Guliyev C., Ince-Guliyev E., Ögel K., p. 358-367.
- Sexual orientation and synthetic cannabinoid use: Examining the role of bullying victimization. Stogner J., Sarvey L., Lowe C.C., Hupli A., Miller B.L., p. 368-377.
- Anxiety-related symptoms following the sporadic use of ecstasy - A case study. Majic T., Brandt L., Montag C., p. 378-385.
- Management of pregabalin use disorder: A case series. Langlumé L., Eiden C., Roy S., Taruffi F., Gambier J., Donnadieu-Rigole H., et al., p. 386-391.
Cote :
Abonnement
Dépouillements
Ajouter le résultat à votre sélection
G. CHEN
|
2022
Dans Journal of Psychoactive Drugs (Vol.54, n°4, September-October 2022) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.54, n°4, September-October 2022) Article : Périodique
Long-term recovery (LTR) from substance use disorders (SUDs) has been described as a complex process. It has been proposed that psychological mechanisms can influence the resolution of problematic substance using behaviors and may explain how an[...]
L. LANGLUME ;
C. EIDEN ;
S. ROY ;
F. TARUFFI ;
J. GAMBIER ;
H. DONNADIEU-RIGOLE ;
H. PEYRIERE
|
2022
Dans Journal of Psychoactive Drugs (Vol.54, n°4, September-October 2022) Article : Périodique
Dans Journal of Psychoactive Drugs (Vol.54, n°4, September-October 2022) Article : Périodique
Pregabalin is indicated for the treatment of partial epilepsy, generalized anxiety disorder, and neuropathic pain. The first reports on pregabalin use disorder have been published in Europe in 2010 and notified to the French Addictovigilance Net[...]